| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6-Chloropyridin-3-amine does not have a defined biological target as it is a synthetic intermediate rather than a pharmacologically active drug. Its role in medicinal chemistry is to serve as a building block for the construction of drug candidates that target specific enzymes or receptors. When incorporated into pharmaceutical compounds, the pyridine ring can participate in hydrogen bonding, π-π stacking, and hydrophobic interactions with protein targets. The amino group can form hydrogen bonds with active site residues, while the chlorine atom can contribute to binding affinity through halogen bonding or lipophilic interactions. The compound itself is not evaluated for biological activity.
|
|---|---|
| ln Vitro |
As a chemical intermediate, 6-chloropyridin-3-amine exhibits no intrinsic pharmacological activity in vitro. Its utility is demonstrated in synthetic chemistry, where it achieves 96% isolated Suzuki-Miyaura coupling yield under optimized conditions. In medicinal chemistry research, the compound is used to synthesize libraries of compounds that are subsequently screened for biological activity against various targets. The compound itself is not tested in cell-based assays for pharmacological effects. Its value lies in its ability to introduce a chloropyridine moiety into drug-like molecules, enabling further functionalization and optimization of lead compounds.
|
| ln Vivo |
6-Chloropyridin-3-amine does not exhibit in vivo biological activity as it is not a therapeutic agent. The compound is used exclusively as a chemical intermediate in the synthesis of pharmaceuticals and agrochemicals. Any in vivo effects would be associated with the final drug products synthesized from this intermediate, not with the intermediate itself. The compound is not administered to animals in pharmacological studies and has no known physiological effects. Its role is strictly chemical—providing a versatile platform for the construction of complex heterocyclic drug candidates with diverse therapeutic applications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed with 6-chloropyridin-3-amine as it is not a biologically active test compound. Standard characterization protocols for this reagent include nuclear magnetic resonance (¹H NMR, ¹³C NMR) and mass spectrometry to confirm structure and purity. Melting point determination and HPLC analysis are used for quality control. For Suzuki-Miyaura coupling reactions, typical conditions involve reacting the compound with arylboronic acids or esters in the presence of a palladium catalyst and a base. The resulting biaryl products are then evaluated for biological activity in appropriate assays.
|
| Cell Assay |
Cell-based experiments are not conducted with 6-chloropyridin-3-amine itself, as it is a chemical reagent rather than a test compound for biological activity. When the compound is used to synthesize drug candidates, those products may be tested in cell culture using standard protocols. Typically, final compounds are dissolved in DMSO and diluted in culture medium to achieve desired concentrations (typically 0.1-100 µM). Cells are incubated for 24-72 hours, and effects on cell viability, proliferation, or specific signaling pathways are measured using appropriate assays such as MTT, Western blotting, or reporter gene assays. The intermediate itself is not evaluated in cellular systems.
|
| Animal Protocol |
In vivo animal studies are not conducted with 6-chloropyridin-3-amine, as it is a research reagent for chemical synthesis. When the compound is used to synthesize drug candidates, those final products undergo standard preclinical evaluation. Typical protocols for drug candidates include pharmacokinetic studies in rodents (oral or intravenous administration, blood sampling for LC-MS/MS analysis), efficacy studies in disease models (e.g., tumor xenografts, inflammation models), and toxicology studies (acute and repeated-dose toxicity, histopathology). These studies evaluate the safety and efficacy of the final drug molecules, not the synthetic intermediate used in their preparation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-chloropyridin-3-amine are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 128.56, logP approximately 1.5, moderate water solubility), the compound would be expected to have moderate oral bioavailability if administered. It would likely undergo metabolism via cytochrome P450-mediated oxidation and conjugation reactions. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies. For drug candidates synthesized from this intermediate, pharmacokinetic properties are determined as part of the drug development process.
|
| Toxicity/Toxicokinetics |
Toxicological data for 6-chloropyridin-3-amine are limited as it is a research reagent. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound contains a chlorinated pyridine ring, which may present hazards if ingested, inhaled, or absorbed through the skin. No acute toxicity data are available. The compound is not intended for drug, household, or other uses. It should be stored in a cool, dry place away from light and moisture.
|
| Additional Infomation |
3-Amino-6-chloropyridine is an aminopyridine.
6-Chloropyridin-3-amine is a widely used building block in medicinal chemistry and agrochemical synthesis. It is extensively employed in the synthesis of kinase inhibitors, antimicrobial agents, and CNS-active compounds. The compound is also known as 3-amino-6-chloropyridine and 5-amino-2-chloropyridine. Its electron-rich amino group and electron-withdrawing chlorine provide a versatile platform for further functionalization via amidation, sulfonylation, alkylation, and cross-coupling reactions. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—serving as a precursor for the synthesis of biologically active molecules. |
| Molecular Formula |
C5H5CLN2
|
|---|---|
| Molecular Weight |
128.56
|
| Exact Mass |
128.014
|
| CAS # |
5350-93-6
|
| PubChem CID |
79305
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
292.6±20.0 °C at 760 mmHg
|
| Melting Point |
81-83 °C(lit.)
|
| Flash Point |
130.7±21.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
0.88
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
76.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])N=1)N([H])[H]
|
| InChi Key |
QAJYCQZQLVENRZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5ClN2/c6-5-2-1-4(7)3-8-5/h1-3H,7H2
|
| Chemical Name |
6-chloropyridin-3-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.7785 mL | 38.8923 mL | 77.7847 mL | |
| 5 mM | 1.5557 mL | 7.7785 mL | 15.5569 mL | |
| 10 mM | 0.7778 mL | 3.8892 mL | 7.7785 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
